Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A pediatric oncology group study

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 413-418

  Marina, Neyssa M ^a   Cochrane, Debon ^a   Harney, Elaine ^b   Zomorodi, Katie ^b   Blaney, Susan ^c   Winick, Naomi ^d   Bernstein, Mark ^e   Link, Michael P ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ALZA CORPORATION   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; RANITIDINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; DERMATITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GLIOMA; HUMANS; LIPOSOMES; MALE; NEUROBLASTOMA; POLYETHYLENE GLYCOLS; RHABDOMYOSARCOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036188460     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Therapeutic effect and toxicity of Adriamycin in patients with neoplastic disease
2. Phase II evaluation of Adriamycin in human neoplasia
3. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma
4. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
5. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
6. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes
7. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
8. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended cimulation times
9. Liposomal drug formulations. Rationale for development and what we can expect for the future
10. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs
11. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
12. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
13. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes
14. Tailoring liposomes for cancer drug delivery: From the bench to the clinic
15. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid
16. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
17. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
18. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
19. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
20. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
21. 2
22. Evaluation of toxicity: Clinical issues
23. A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
24. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas
25. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours
26. Doxorubicin disposition in children and adolescents with cancer
27. Pharmacokinetics of anticancer drugs in children
28. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure
29. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
30. Phase I trials of dexrazoxane and other potential applications for the agent
31. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
32. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive care